MARVELD3 inhibits the epithelial‐mesenchymal transition and cell migration by suppressing the Wnt/β‐catenin signaling pathway in non–small cell lung cancer cells
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.14844 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Shirong Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The epithelial‐mesenchymal transition (EMT), featured by abatement of cell–cell contact, is related to exacerbating non–small cell lung cancer (NSCLC) by inducing metastasis. MAL and relevant proteins for vesicle trafficking and membrane link domain 3 (MARVELD3) is a novel tight junction protein participated in the EMT. There is limited information available about the mechanism of MARVELD3 in NSCLC. In this trial, the inhibition effect of MARVELD3 on human NSCLC cells will be discussed.
Methods
MARVELD3 expression was measured in NSCLC tissues and para‐carcinoma tissues. The expression of MARVELD3 and EMT‐related genes were examined in transforming growth factor (TGF)‐β1‐induced NSCLC cells. NSCLC cells with MARVELD3‐knockdown and overexpressed were established to analyze the relationship between MARVELD3 and EMT and cell migration. The Wnt/β‐catenin pathway expression was also analyzed in NSCLC cell models and clinic species.
Results
Lower protein levels of MARVELD3 were observed in NSCLC samples than para‐carcinoma specimens, and the decreased expression of MARVELD3 in NSCLC specimens was associated with tumor metastasis. E‐Cadherin and MARVELD3 expression was reduced in TGF‐β1 treated NSCLC cells, whereas increased Vimentin expression was detected. MARVELD3 changed the EMT‐related genes and induced cell migration. In addition, Wnt/β‐catenin pathway and target genes, MYC and CCND1, expressions were inhibited in MARVELD3 overexpressed NSCLC cells.
Conclusions
TGF‐β1 induced EMT in human NSCLC cells can be suppressed by MARVELD3 through Wnt/β‐catenin signaling pathway. These results indicate that MARVELD3 might be a potential therapeutic modality useful in the treatment of NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Beijing Institute of Clinical medicine Research, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Respiratory Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Shirong Li, Saiping Qi, Yanmeng Li, Chunpan Zhang, Lan Sun, Chunquan Liu, Haoyan Wang
Zitieren
APA
Li, S., Qi, S., Li, Y., Zhang, C., Sun, L., Liu, C., & Wang, H. (2023). MARVELD3 inhibits the epithelial‐mesenchymal transition and cell migration by suppressing the Wnt/β‐catenin signaling pathway in non–small cell lung cancer cells. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14844
Vancouver
Li S, Qi S, Li Y, Zhang C, Sun L, Liu C, et al. MARVELD3 inhibits the epithelial‐mesenchymal transition and cell migration by suppressing the Wnt/β‐catenin signaling pathway in non–small cell lung cancer cells. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14844
BibTeX
@article{Li2023,
author = {Li, Shirong and Qi, Saiping and Li, Yanmeng and Zhang, Chunpan and Sun, Lan and Liu, Chunquan and Wang, Haoyan},
title = {MARVELD3 inhibits the epithelial‐mesenchymal transition and cell migration by suppressing the Wnt/β‐catenin signaling pathway in non–small cell lung cancer cells},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.14844}
}
EUVIMED